Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more

Recent & Breaking News (TSX:MDNA)

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

GlobeNewswire November 9, 2023

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 6, 2023

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 3, 2023

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

GlobeNewswire October 27, 2023

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

GlobeNewswire October 25, 2023

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

GlobeNewswire October 24, 2023

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

GlobeNewswire October 10, 2023

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

GlobeNewswire October 3, 2023

Medicenna Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire September 28, 2023

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

GlobeNewswire September 28, 2023

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

GlobeNewswire August 28, 2023

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

GlobeNewswire August 14, 2023

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

GlobeNewswire August 9, 2023

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee 

GlobeNewswire August 8, 2023

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

GlobeNewswire August 4, 2023

Medicenna Therapeutics notches U.S. patent for BiSKIT platform

Jocelyn Aspa August 1, 2023

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

GlobeNewswire August 1, 2023

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

GlobeNewswire July 28, 2023

Medicenna Presents at National Brain Tumor Society's Research Round Table

GlobeNewswire July 25, 2023